Prevalence rate of non-obese fatty liver disease and related influencing factors

Jiang DENG; Zhiyi HAN; Cailan XIAO; Yating SUN; Yajun JI; Li AO; Yonghong ZHANG; Xiaolan LU

doi:10.3969/j.issn.1001-5256.2021.11.022

Volume 37 Issue 11

Nov. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(11): 2600-2604

PDF( 1908 KB)

Prevalence rate of non-obese fatty liver disease and related influencing factors

DOI: 10.3969/j.issn.1001-5256.2021.11.022

Jiang DENG^1a,
Zhiyi HAN^2a,
Cailan XIAO^1b,
Yating SUN^1b,
Yajun JI³,
Li AO³,
Yonghong ZHANG^{2b
,
,},
Xiaolan LU^{1b, 3
,
,}

1a.
Department of Infectious Diseases, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
1b.
Department of Gastroenterology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
2a.
Department of Gastroenterology, Karamay Central Hospital, Karamay, Xinjiang 834099, China
2b.
Physical Examination Center, Karamay Central Hospital, Karamay, Xinjiang 834099, China
3.
Department of Gastroenterology, Pudong Hospital Affiliated to Fudan University, Shanghai 201399, China

Research funding:

Shanghai Natural Science Foundation of China (20ZR1450100);

Talents Training Program of Pudong Hospital affiliated to Fudan University (YJRCJJ201801);

the Fundamental Research Funds for the Central Universities (xjh012019063);

National Key Research and Development Program of China during the 13th Five-Year Plan Period (2018YFC1311504)

Received Date: 2021-04-05
Accepted Date: 2021-04-28
Published Date: 2021-11-20

Abstract

Abstract

Objective To investigate the prevalence rate of non-obese fatty liver disease and its influencing factors, and to provide a reference for the prevention and treatment of fatty liver disease. Methods A total of 23 545 individuals who underwent physical examination in Karamay Central Hospital from January to December 2015 and had complete data of abdominal ultrasound, body mass index (BMI), age, and sex were screened out to analyze the prevalence rate of fatty liver disease, and 7484 individuals with normal BMI who had complete data of triglyceride (TG), fasting blood glucose, and alanine aminotransferase (ALT) were further screened out to perform a multivariate analysis. The t-test was used for comparison of normally distributed continuous data between two groups, and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups; the chi-square test was used for comparison of categorical data between groups. A multivariate logistic regression analysis was performed to investigate independent influencing factors for non-obese fatty liver disease. Results In 2015, the prevalence rate of fatty liver disease was 30.2% (7116/23 545) among the individuals who underwent physical examination in Karamay Central Hospital. A stratified analysis based on BMI showed that the individuals with emaciation, normal BMI, overweight, and obesity had a prevalence rate of 0.8% (6/706), 9.3% (919/9899), 38.4% (3404/8870), and 68.5% (2787/4070), respectively (all P < 0.05), and male individuals had a significantly higher prevalence rate of fatty liver disease than female individuals (all P < 0.05). Among the 919 patients with non-obese fatty liver disease, young, middle-aged, and elderly patients accounted for 40.7% (374/919), 46.1% (424/919), and 13.2% (121/919), respectively. For the individuals with normal BMI, there was no significant difference in the prevalence rate of fatty liver disease between middle-aged and elderly individuals (14.5% vs 16.8%, P > 0.05), while both of them had a significantly higher prevalence rate than the young individuals (14.5%/16.8% vs 6.0%, P < 0.05). Young and middle-aged male individuals had a significantly higher prevalence rate of fatty liver disease than their female counterparts (χ²=99.40 and 43.29, both P < 0.001), while the elderly male individuals had a significantly lower prevalence rate than their female counterparts (χ²=9.81, P=0.002). For the individuals with normal BMI, the individuals with normal TG had a prevalence rate of fatty liver disease of 5.0% (311/6273), while those with elevated TG had a prevalence rate of 26.8% (325/1211), with a significant difference between the two groups (χ²=624.90, P < 0.001). The multivariate logistic regression analysis showed that age, BMI, ALT, fasting blood glucose, TG, and serum uric acid level were independent influencing factors for fatty liver disease in individuals with normal BMI (all P < 0.001). Conclusion There is a relatively high prevalence rate of non-obese fatty liver disease among individuals undergoing physical examination in Karamay Central Hospital, and 61.5% of the patients with non-obese fatty liver disease have glucose or lipid metabolic disorders. Serum TG level may be used as a simple and effective screening index for non-obese fatty liver disease.
- Fatty Liver Disease,
- Prevalence,
- Risk Factors

FullText(HTML)

References(21)

References

[1]	YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64(1): 73-84. DOI: 10.1002/hep.28431.
[2]	WANG XJ, MALHI H. Nonalcoholic fatty liver disease[J]. Ann Intern Med, 2018, 169(9): ITC65-65ITC80. DOI: 10.7326/AITC201811060.
[3]	TOMIC D, KEMP WW, ROBERTS SK. Nonalcoholic fatty liver disease: Current concepts, epidemiology and management strategies[J]. Eur J Gastroenterol Hepatol, 2018, 30(10): 1103-1115. DOI: 10.1097/MEG.0000000000001235.
[4]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34(5): 947-957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[5]	KWOK R, CHOI KC, WONG GL, et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: A prospective cohort study[J]. Gut, 2016, 65(8): 1359-1368. DOI: 10.1136/gutjnl-2015-309265.
[6]	GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet, 2020, 396(10258): 1223-1249. DOI: 10.1016/S0140-6736(20)30752-2.
[7]	LI Z, XUE J, CHEN P, et al. Prevalence of nonalcoholic fatty liver disease in mainland of China: A meta-analysis of published studies[J]. J Gastroenterol Hepatol, 2014, 29(1): 42-51. DOI: 10.1111/jgh.12428.
[8]	LIN S, XIAN Y, LIU Y, et al. Risk factors and community intervention for nonalcoholic fatty liver disease in community residents of Urumqi, China[J]. Medicine (Baltimore), 2018, 97(9): e0021. DOI: 10.1097/MD.0000000000010021.
[9]	WANG L, WU GL, GE L. Investigation of fatty liver in health examination of residents in Kuytun area[J]. Bull Dis Control Prev(CHINA), 2018, 33(2): 54-55, 58. DOI: 10.13215/j.cnki.jbyfkztb.1712001. 王琳, 吴桂玲, 葛亮. 奎屯地区居民健康体检脂肪肝的调查[J]. 疾病预防控制通报, 2018, 33(2): 54-55, 58. DOI: 10.13215/j.cnki.jbyfkztb.1712001.
[10]	YE Q, ZOU B, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5(8): 739-752. DOI: 10.1016/S2468-1253(20)30077-7.
[11]	CHEN HT, ZHOU YJ. Diagnosis and therapeutic strategies for non-obese type of non-alcoholic fatty liver diseases[J]. Chin J Hepatol, 2020, 28(3): 203-207. DOI: 10.3760/cma.j.cn501113-20191226-00480. 陈慧婷, 周永健. 非肥胖型非酒精性脂肪性肝病的诊治对策[J]. 中华肝脏病杂志, 2020, 28(3): 203-7. DOI: 10.3760/cma.j.cn501113-20191226-00480.
[12]	HA Y, SEO N, SHIM JH, et al. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study[J]. J Gastroenterol Hepatol, 2015, 30(11): 1666-1672. DOI: 10.1111/jgh.12996.
[13]	TIAN T, HU WW, LI X, et al. Metabolic characteristics of nonalcoholic fatty liver disease and related risk factors in non-obese population[J]. J Clin Hepatol, 2020, 36(6): 1310-1313. DOI: 10.3969/j.issn.1001-5256.2020.6.024. 田甜, 胡文炜, 李雪, 等. 非肥胖人群非酒精性脂肪性肝病代谢特征及危险因素分析[J]. 临床肝胆病杂志, 2020, 36(6): 1310-1313. DOI: 10.3969/j.issn.1001-5256.2020.06.024.
[14]	COTTER TG, RINELLA M. Nonalcoholic fatty liver disease 2020: The state of the disease[J]. Gastroenterology, 2020, 158(7): 1851-1864. DOI: 10.1053/j.gastro.2020.01.052.
[15]	YOUNOSSI Z, ANSTEE QM, MARIETTI M, et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention[J]. Nat Rev Gastroenterol Hepatol, 2018, 15(1): 11-20. DOI: 10.1038/s41575-020-00381-6.
[16]	ARNER P, BERNARD S, APPELSVED L, et al. Adipose lipid turnover and long-term changes in body weight[J]. Nat Med, 2019, 25(9): 1385-1389. DOI: 10.1038/s41591-019-0565-5.
[17]	PALMISANO BT, ZHU L, ECKEL RH, et al. Sex differences in lipid and lipoprotein metabolism[J]. Mol Metab, 2018, 15: 45-55. DOI: 10.1016/j.molmet.2018.05.008.
[18]	BRADY CW. Liver disease in menopause[J]. World J Gastroenterol, 2015, 21(25): 7613-7620. DOI: 10.3748/wjg.v21.i25.7613.
[19]	VENETSANAKI V, POLYZOS SA. Menopause and non-alcoholic fatty liver disease: A review focusing on therapeutic perspectives[J]. Curr Vasc Pharmacol, 2019, 17(6): 546-555. DOI: 10.2174/1570161116666180711121949.
[20]	LI YY, XIE ZY. Advances in the etiology and treatment of non-obese nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2021, 37(2): 452-457. DOI: 10.3969/j.issn.1001-5256.2021.02.043. 李洋洋, 谢正元. 非肥胖型非酒精性脂肪性肝病的病因及治疗进展[J]. 临床肝胆病杂志, 2021, 37(2): 452-457. DOI: 10.3969/j.issn.1001-5256.2021.02.043.
[21]	HUANG Y, HUANG ZG. Analysis on epidemiological characteristics of circulatory disease mortality, Karamay city, 2018[J]. Pre Med Trib, 2020, 26(4): 290-292. DOI: 10.16406/j.pmt.issn.1672-9153.2020.04.015. 黄芸, 黄志光. 2018年克拉玛依市循环系统疾病死亡流行特征分析[J]. 预防医学论坛, 2020, 26(4): 290-292. DOI: 10.16406/j.pmt.issn.1672-9153.2020.04.015.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(4)

Get Citation

PDF

XML

Article Metrics

Article views (567) PDF downloads(83)

Prevalence rate of non-obese fatty liver disease and related influencing factors

DOI: 10.3969/j.issn.1001-5256.2021.11.022

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Prevalence rate of non-obese fatty liver disease and related influencing factors

DOI: 10.3969/j.issn.1001-5256.2021.11.022

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content